

**Company registration number: 357306**

**Rosspharm Limited  
Trading as Rosspharm Limited**

**Unaudited abridged financial statements  
for the financial year ended 30 April 2025**

# Rosspharm Limited

## Contents

	<b>Page</b>
Directors and other information	<b>1</b>
Directors responsibilities statement	<b>2</b>
Balance sheet	<b>3</b>
Notes to the financial statements	<b>4 - 5</b>

## Rosspharm Limited

### Directors and other information

<b>Directors</b>	Alan Kelleher Deborah Kelleher
<b>Secretary</b>	Alan Kelleher
<b>Company number</b>	357306
<b>Registered office</b>	Kelleher's Pharmacy, Main Street, Ballincollig, Co. Cork.
<b>Business address</b>	Kelleher's Pharmacy Main Street, Ballincollig, Co. Cork
<b>Accountant</b>	T.F.Hinchy 23 Wilton Gardens Wilton Road Cork
<b>Bankers</b>	AIB Bank 66 South Mall Cork Co. Cork  Bank of Ireland Ballincollig Co. Cork
<b>Solicitors</b>	O'Cathain and Company 30 South Terrace Cork Co.Cork

## **Rosspharm Limited**

### **Directors responsibilities statement**

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

Company law requires the directors to prepare financial statements for each financial year. Under that law, they have elected to prepare the financial statements in accordance with FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime (FRS 105).

As such the directors are responsible for preparing financial statements in accordance with the provisions of the Companies Act 2014 with which the company is obliged to comply, including the appropriate use of the going concern basis of accounting, which is consistent with those requirements, and having availed of the exemptions to which the company is entitled by virtue of qualifying for the micro companies regime and FRS 105. Thereby, the financial statements are presumed, in law, to give a true and fair view without any consideration of any other circumstances, factors, accounting principles or disclosures.

The directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the company and enable them to ensure that the financial statements comply with the Companies Act 2014. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities.

**Rosspharm Limited**

**Balance sheet  
As at 30 April 2025**

	2025		2024	
	€	€	€	€
Current assets	1,090		3,622	
Prepayments and accrued income	2,700		2,700	
	<u>3,790</u>		<u>6,322</u>	
Creditors: amounts falling due within one year		(821,696)		(814,806)
<b>Net current liabilities</b>		<u>(817,906)</u>		<u>(808,484)</u>
<b>Total assets less current liabilities</b>		(817,906)		(808,484)
Accruals and deferred income		(6,270)		(10,040)
<b>Net liabilities</b>		<u>(824,176)</u>		<u>(818,524)</u>
<b>Capital and reserves</b>		<u>(824,176)</u>		<u>(818,524)</u>

We, as directors of Rosspharm Limited state that:

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- (c) the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- (e) the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a micro company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements have been prepared in accordance with the micro companies regime.

These abridged financial statements were approved by the board of directors on 11 February 2026 and signed on behalf of the board by:

**Alan Kelleher**  
Director

**Deborah Kelleher**  
Director

## Rosspharm Limited

### Notes to the abridged financial statements Financial year ended 30 April 2025

#### 1. General information

The company is a private company limited by shares, registered in Ireland. The address of the registered office is Kelleher's Pharmacy,, Main Street,, Ballincollig,, Co. Cork..

#### 2. Statement of compliance

These financial statements have been prepared in accordance with FRS 105, 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

#### 3. Accounting policies and measurement bases

##### Basis of preparation

The financial statements have been prepared on the historical cost basis.

The financial statements are prepared in Euro, which is the functional currency of the entity.

##### Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

##### Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Financial instruments are initially recognised at cost, which is the transaction price.

Investments in shares, subsidiaries or participating interests are subsequently measured at cost less impairment.

Derivatives are subsequently measured at the cost plus any transaction costs not immediately recognised in profit or loss less any impairment losses recognised to date. This is allocated to profit or loss over the term of the contract on a straight-line basis, unless another systematic basis of allocation is more appropriate.

Other financial instruments are subsequently measured at the cost plus any transaction costs not immediately recognised in profit or loss, plus accumulated interest income or expense recognised to date, less all repayments of principal or interest to date, less impairment.

Financial assets are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

Any reversals of impairment are recognised in profit or loss immediately.

**Rosspharm Limited**

**Notes to the abridged financial statements (continued)**  
**Financial year ended 30 April 2025**

**4. Appropriations of profit and loss account**

	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
At the start of the financial year	(818,527)	(812,875)
Loss for the financial year	(5,652)	(5,652)
<b>At the end of the financial year</b>	<u>(824,179)</u>	<u>(818,527)</u>

**5. Share Capital**

**Authorised Share Capital**

	<b>2025</b>		<b>2024</b>	
	<b>Number</b>	<b>€</b>	<b>Number</b>	<b>€</b>
Ordinary shares of €1.00 each	100,000	100,000	100,000	100,000
"A" Ordinary shares of €1.00 each	1	1	1	1
	<u>100,001</u>	<u>100,001</u>	<u>100,001</u>	<u>100,001</u>

Called Up share capital

	<b>2025</b>		<b>2024</b>	
	<b>Number</b>	<b>€</b>	<b>Number</b>	<b>€</b>
<b>Amounts presented in equity:</b>				
Ordinary shares of €1.00 each	2	2	2	2
"A" Ordinary shares of €1.00 each	1	1	1	1
	<u>3</u>	<u>3</u>	<u>3</u>	<u>3</u>

On 1 February 2019, the authorised share capital of the company was increased from 100,000 ordinary shares of €1 each to 100,001 comprising 100,000 ordinary shares of €1 each and one "A" ordinary share of €1. On that day, the "A" ordinary share was allotted to Pulse Pharmacy Holdings Limited, Main Street, Ballincollig, Co. Cork.